Phase 1 Rare Disease Trial, Recruiting NCT05607498 Sponsor: EpimAb Biotherapeutics (Suzhou)Co., Ltd. Condition: Rare Disease
Back to Rare Disease

Phase 1 Rare Disease Trial, Recruiting

NCT05607498
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form and follow all study procedures
  • You are 18 years old or older
  • For solid tumour patients (Group A): You have been diagnosed (confirmed by lab testing) with an advanced or spreading cancer that cannot be surgically removed, specifically one of these types: triple-negative breast cancer, lung adenocarcinoma, ovarian cancer, pancreatic cancer, colorectal cancer, stomach cancer, prostate cancer, bladder cancer, or uterine cancer
  • For blood/lymph cancer patients (Group B): You have been diagnosed (confirmed by lab testing) with a returning or treatment-resistant lymphoma, specifically: CLL/SLL, mantle cell lymphoma, or diffuse large B cell lymphoma
  • For Group A: Standard treatments no longer exist, are no longer working, or are not tolerable or available to you, and your disease can be measured or tracked
  • For Group B: You have at least one tumour that can be measured on a scan (CT or MRI), or for CLL patients with no measurable tumours on scans, a specific level of abnormal blood cells is present (confirm with trial site)
  • You are able to provide a stored tumour tissue sample taken within the last 2 years, or you are willing to have a fresh biopsy taken if no recent sample is available
  • You are in good general health and able to carry out everyday activities with little or no limitation (a standard health scale called ECOG 0 or 1)
  • Your organs (such as liver, kidneys, and heart) are functioning well enough to participate
  • Any side effects from previous cancer treatments have cleared up or recovered sufficiently

Who may not be able to join:

  • You have previously been treated with any drug that targets a protein called ROR1
  • You have had a severe immune-related reaction (Grade 4) to a previous cancer treatment, or had to stop a previous treatment because of immune-related side effects
  • You have a cancer that started in the brain or spinal cord, or you currently have symptoms from cancer that has spread to the brain — though some patients with brain spread from solid tumours may still be eligible if certain conditions are met (confirm with trial site)
  • You have received cancer treatment or radiation therapy too recently before starting the study (confirm exact timing with trial site)
  • You currently misuse alcohol, cannabis products, or other drugs

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613758235260

Australian sites

Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria
One Clinical Research, Nedlands, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
31 October 2025

Where this trial is recruiting

🇦🇺 Australia 🇨🇳 China

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence and severity of adverse events as assessed by CTCAE V5.0.; Incidence of serious adverse events (SAE).; Incidence of dose interruptions.; Dose intensity.; The incidence of DLTs during the first cycle of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov